Study links brain signals to Parkinson's compulsive eating in females

Summary

Parkinson's disease is famous for affecting movement, but it can also lead to surprising behavioral changes, like compulsive eating. To understand why, researchers focused on a specific subset of brain cells that produce dopamine, a chemical messenger tied to reward and pleasure. These particular dopamine-producing cells are highly vulnerable in Parkinson's disease. The research team wanted to see what happens when these cells lose their ability to receive signals from glutamate, another chemical messenger that typically stimulates brain activity.

Using mouse models, the scientists genetically removed a crucial receptor called NMDA, which normally acts like a docking station for glutamate signals. While the genetically altered mice still moved normally, a striking difference appeared in the female mice. When the female mice were temporarily restricted from food and then given access again, they displayed excessive reward-seeking behavior. They binged on food and gained weight, a reaction that did not happen in the male mice.

The team traced this compulsive eating behavior to an area of the brain known as the ventral tegmental area, which plays a major role in how we process rewards. Furthermore, genetic sequencing of the brains showed massive shifts in how genes were turned on or off, specifically in the female mice after food restriction. These genetic changes were heavily linked to energy metabolism and the function of mitochondria, the energy factories of the cells.

Why it matters.

This research provides a crucial biological clue into why some patients with Parkinson's disease develop compulsive eating disorders. For years, these behavioral side effects have been a challenging hurdle in clinical settings, deeply impacting patient quality of life. By linking this specific disrupted brain signal to binge eating, scientists now have a potential new pathway to study. Recognizing that this disruption primarily affected female mice also highlights the critical need to consider biological sex when developing targeted treatments for the behavioral symptoms of Parkinson's disease.

However, there is still a long way to go before these insights reach the clinic. This is early-stage preclinical research conducted entirely in mice, and the initial report lacks specific quantitative data on sample sizes. Future studies will need to confirm if these same dopamine and glutamate pathways function similarly in the human brain, but this work sets a fascinating foundation for understanding how brain diseases can alter our relationship with food.

From the source

The story in numbers.

Brain regions evaluated for regional contributions (VTA and SNc): 2
Key NMDAR subunit gene targeted (Grin1): 1

Keep the context

Follow the evidence.

This source is a preprint and has not completed peer review. Its findings are provisional.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

Follow your curiosity.

Study links brain signals to Parkinson's compulsive eating in females

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

A little science goes a long way.